FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224214690> ?p ?o ?g. }

• W4224214690 endingPage "2434" @default.
• W4224214690 startingPage "2428" @default.
• W4224214690 abstract "Radiofrequency catheter ablation (RFCA) is now an established therapeutic option for patients with atrial fibrillation (AF), but the long-term recurrence rate of AF is still high. Sacubitril/valsartan (Sac/Val) is superior to valsartan in attenuating ventricular remodelling and improving clinical outcomes in heart failure patients, but whether this additional benefit exists in reversing atrial remodelling and reducing AF recurrence of RFCA-treated AF patients remains uncovered.Patients that had undergone RFCA were enrolled and randomly assigned 1:1 to valsartan (160 mg/day) or Sac/Val (200 mg/day) treatment group, in addition to other standard treatment of AF. Patients were followed up for 24 weeks. Echocardiography and ambulatory Holter monitoring for 24 h was performed at 24 weeks after RFCA. The primary end point was the change of atrial diameter from baseline to 24 weeks after RFCA. Second end points included the recurrence rate of AF, all-cause hospitalization and all-cause death. A total of 64 AF patients were enrolled, 32 of which received Sac/Val and 32 received valsartan treatment. There was no difference in the age (64.8 ± 9.8 vs. 63.7 ± 9.0, P = 0.634), gender (per cent of male: 59.4% vs. 50.0%, P = 0.616), heart rate (84.7 ± 4.1 b.p.m. vs. 80.9 ± 2.6 b.p.m., P = 0.428), systolic (127.5 ± 15.4 mmHg vs. 130.0 ± 17.8 mmHg, P = 0.549) or diastolic (81.7 ± 9.8 mmHg vs. 79.9 ± 12.6, P = 0.537) blood pressure upon admission between valsartan and Sac/Val treatment groups. The percentage of persistent AF was also comparable (43.8% vs. 53.1%, P = 0.617) in both treatment groups. Patients receiving Sac/Val treatment displayed significant decrease in the left atrial diameter (4.3 ± 0.5 cm to 3.8 ± 0.5 cm, P < 0.001), volume index (48.0 ± 6.4 mL/m2 to 41.7 ± 7.0 mL/m2 , P < 0.001), and right atrial diameter (4.4 ± 0.8 cm to 3.9 ± 0.7 cm, P = 0.017) from baseline to 24 weeks after RFCA. This effect was not observed in valsartan treatment group. There was a numerical decrease in AF recurrence rate in the Sac/Val group compared with valsartan group (9.4% vs. 15.6%), although this difference did not reach a statistical significance (P = 0.708). No difference in all-cause hospitalization rate (6.3% in each group) or all-cause death rate (0% in each group) was observed.Our data indicate that Sac/Val is superior to valsartan in attenuating atrial structural remodelling in catheter ablation-treated AF patients." @default.
• W4224214690 created "2022-04-26" @default.
• W4224214690 creator A5000750769 @default.
• W4224214690 creator A5009374251 @default.
• W4224214690 creator A5010465278 @default.
• W4224214690 creator A5053204257 @default.
• W4224214690 date "2022-04-18" @default.
• W4224214690 modified "2023-10-16" @default.
• W4224214690 title "Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients" @default.
• W4224214690 cites W1556408220 @default.
• W4224214690 cites W164951247 @default.
• W4224214690 cites W1963523656 @default.
• W4224214690 cites W2058986936 @default.
• W4224214690 cites W2062316006 @default.
• W4224214690 cites W2098418963 @default.
• W4224214690 cites W2101099004 @default.
• W4224214690 cites W2108772064 @default.
• W4224214690 cites W2111995867 @default.
• W4224214690 cites W2113698123 @default.
• W4224214690 cites W2116655536 @default.
• W4224214690 cites W2117629410 @default.
• W4224214690 cites W2119268070 @default.
• W4224214690 cites W2137627374 @default.
• W4224214690 cites W2147018083 @default.
• W4224214690 cites W2156207648 @default.
• W4224214690 cites W2159555195 @default.
• W4224214690 cites W2614763070 @default.
• W4224214690 cites W2757773166 @default.
• W4224214690 cites W2791537800 @default.
• W4224214690 cites W2899166932 @default.
• W4224214690 cites W2899841238 @default.
• W4224214690 cites W2970357473 @default.
• W4224214690 cites W2982129752 @default.
• W4224214690 cites W3016940193 @default.
• W4224214690 cites W3082188176 @default.
• W4224214690 cites W3124689299 @default.
• W4224214690 cites W4224214690 @default.
• W4224214690 cites W4234327319 @default.
• W4224214690 cites W4246064375 @default.
• W4224214690 cites W4365787934 @default.
• W4224214690 doi "https://doi.org/10.1002/ehf2.13937" @default.
• W4224214690 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35437929" @default.
• W4224214690 hasPublicationYear "2022" @default.
• W4224214690 type Work @default.
• W4224214690 citedByCount "8" @default.
• W4224214690 countsByYear W42242146902022 @default.
• W4224214690 countsByYear W42242146902023 @default.
• W4224214690 crossrefType "journal-article" @default.
• W4224214690 hasAuthorship W4224214690A5000750769 @default.
• W4224214690 hasAuthorship W4224214690A5009374251 @default.
• W4224214690 hasAuthorship W4224214690A5010465278 @default.
• W4224214690 hasAuthorship W4224214690A5053204257 @default.
• W4224214690 hasBestOaLocation W42242146902 @default.
• W4224214690 hasConcept C126322002 @default.
• W4224214690 hasConcept C164705383 @default.
• W4224214690 hasConcept C203092338 @default.
• W4224214690 hasConcept C2775914520 @default.
• W4224214690 hasConcept C2776131983 @default.
• W4224214690 hasConcept C2776754050 @default.
• W4224214690 hasConcept C2777387769 @default.
• W4224214690 hasConcept C2778198053 @default.
• W4224214690 hasConcept C2779161974 @default.
• W4224214690 hasConcept C35785553 @default.
• W4224214690 hasConcept C535046627 @default.
• W4224214690 hasConcept C71924100 @default.
• W4224214690 hasConcept C84393581 @default.
• W4224214690 hasConceptScore W4224214690C126322002 @default.
• W4224214690 hasConceptScore W4224214690C164705383 @default.
• W4224214690 hasConceptScore W4224214690C203092338 @default.
• W4224214690 hasConceptScore W4224214690C2775914520 @default.
• W4224214690 hasConceptScore W4224214690C2776131983 @default.
• W4224214690 hasConceptScore W4224214690C2776754050 @default.
• W4224214690 hasConceptScore W4224214690C2777387769 @default.
• W4224214690 hasConceptScore W4224214690C2778198053 @default.
• W4224214690 hasConceptScore W4224214690C2779161974 @default.
• W4224214690 hasConceptScore W4224214690C35785553 @default.
• W4224214690 hasConceptScore W4224214690C535046627 @default.
• W4224214690 hasConceptScore W4224214690C71924100 @default.
• W4224214690 hasConceptScore W4224214690C84393581 @default.
• W4224214690 hasFunder F4320321001 @default.
• W4224214690 hasIssue "4" @default.
• W4224214690 hasLocation W42242146901 @default.
• W4224214690 hasLocation W42242146902 @default.
• W4224214690 hasLocation W42242146903 @default.
• W4224214690 hasOpenAccess W4224214690 @default.
• W4224214690 hasPrimaryLocation W42242146901 @default.
• W4224214690 hasRelatedWork W2604998822 @default.
• W4224214690 hasRelatedWork W2868803160 @default.
• W4224214690 hasRelatedWork W2884132894 @default.
• W4224214690 hasRelatedWork W2972799805 @default.
• W4224214690 hasRelatedWork W2981327070 @default.
• W4224214690 hasRelatedWork W2997776967 @default.
• W4224214690 hasRelatedWork W2999054836 @default.
• W4224214690 hasRelatedWork W3024855101 @default.
• W4224214690 hasRelatedWork W3185488917 @default.
• W4224214690 hasRelatedWork W3209057552 @default.
• W4224214690 hasVolume "9" @default.
• W4224214690 isParatext "false" @default.

• next